New CDMO acquisition for Keensight Capital Keensight Capital, a leading Paris-based private equity managers dedicated to pan-European Growth Buyout investments, has just acquired Infarco’s majority stake in 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics. Founded in 2006 and based near Pamplona, Spain,…..
New collaboration to "silence" the complement cascade Mallinckrodt and Silence Therapeutics will collaborate to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins…..
Rescue, a new CRISPR platform to expand RNA editing capabilities The new system, dubbed RESCUE, allows RNA edits to be made that were not previously possible. [caption id="attachment_9342" align="aligncenter" width="1024"] The CRISPR family enzyme Cas13 at work. Cas13 (pink), is at the heart of the RESCUE platform, where it uses…..
Debiopharm and BIOASTER join forces against infectious diseases The Swiss biopharmaceutical company Debiopharm and BIOASTER, the French Technology Research Institute in infectiology have officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. This relationship will harness BIOASTER’s scientific and technical expertise, including technology platforms,…..